North American Contact Dermatitis Group Patch Test Results 2013–2014
- 1 February 2017
- journal article
- studies
- Published by SAGE Publications in Dermatitis®
- Vol. 28 (1) , 33-46
Abstract
Background: Patch testing is the most important diagnostic tool for the assessment of allergic contact dermatitis. Objective: This study documents the North American Contact Dermatitis Group (NACDG) patch testing results from January 1, 2013, to December 31, 2014. Methods: At 13 centers in North America, patients were tested in a standardized manner with a screening series of 70 allergens. Data were manually verified and entered into a central database. Descriptive frequencies were calculated, and trends were analyzed using χ 2 test. Results: A total of 4871 patients were tested. There were 3255 patients (66.8%) who had at least 1 positive reaction and 2412 patients (49.5%) who were ultimately determined to have a primary diagnosis of allergic contact dermatitis. A total of 434 patients (8.9%) had occupationally related skin disease. There were 9726 positive allergic reactions. Compared with the previous reporting periods (2011–2012 and 2001–2012, including at least three 2-year cycles), positive reaction rates for the top 25 screening allergens statistically increased for 2 allergens: methylchloroisothiazolinone/methylisothiazolinone (6.4%; risk ratios, 1.26 [1.07–1.50] and 2.08 [1.84–2.37]) and hydroxyethyl methacrylate (2.6%; risk ratios, 1.34 [1.02–1.76] and 1.23 [1.00–1.51]). Methylisothiazolinone, which was added to the screening series for this 2013–2014 cycle, had the third highest positive reaction rate of allergens tested (10.9%). Four other newly added allergen preparations—formaldehyde 2% (7%), diphenylguanidine (3.8%), propylene glycol 100% (2.8%), and benzophenone-4 (2.1%)—all had reaction rates greater than 2%. Twenty-one percent of tested patients had at least 1 relevant allergic reaction to an allergen not on the NACDG series; 14.6% of these were occupationally related. The T.R.U.E. TEST (SmartPractice Denmark, Hillerød, Denmark) would have hypothetically missed one quarter to one third of reactions detected by the NACDG screening series. Conclusions: These results confirm that the epidemic of sensitivity to methylisothiazolinone previously documented in Europe is also occurring in North America. Patch testing with allergens beyond a standard screening tray is necessary for the complete evaluation of occupational and nonoccupational allergic contact dermatitis.Keywords
This publication has 34 references indexed in Scilit:
- North American Contact Dermatitis Group Patch Test Results: 2011–2012Dermatitis®, 2015
- North American Contact Dermatitis Group Patch Test Results: 2009 to 2010Dermatitis®, 2013
- North American Contact Dermatitis Group Patch Test Results for 2007–2008Dermatitis®, 2013
- North American Contact Dermatitis Group Patch-Test Results, 1998 to 2000Dermatitis®, 2003
- North American Contact Dermatitis Group Patch-Test Results, 1996-1998Archives of Dermatology, 2000
- North American Contact Dermatitis Group standard tray patch test results (1992 to 1994)Dermatitis®, 1995
- Patch Testing With a Routine Screening Tray in North America, 1985 Through 1989: I. Frequency of ResponseDermatitis®, 1991
- Prevalence and relevance of allergic reactions in patients patch tested in North America—1984 to 1985Journal of the American Academy of Dermatology, 1989
- The frequency of contact sensitivity in North America 1972–74 North American Contact Dermatitis GroupContact Dermatitis, 1975
- Epidemiology of Contact Dermatitis in North America: 1972Archives of Dermatology, 1973